Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Subconjunctival bevacizumab injections combined with conjunctival autograft for primary pterygium excision

Poster Details

First Author: E. Stangogianni GREECE

Co Author(s):    C. Stangogianni                    

Abstract Details


To demonstrate the efficacy and safety of subconjunctival bevacizumab injection combined with conjunctival autograft as an adjuvant therapy for primary pterygium.


Laserlens. Ophthalmology Institute, Ioannina Greece


A prospective, comparative, blind, interventional study was carried out from January 2014 until December 2015. One hundred eyes of 100 patients with primary pterygia were included in the study. Patients were randomly assigned to undergo conjunctival autograft with 0.1 ml balanced salt solution (Group A) and conjunctival autograft with 2.5 mg/0.1 ml subconjunctival bevacizumab injection (Group B). Each group consisted of 50 eyes. Recurrence rates at 1 year were evaluated.


Fifty patients were assigned to each group. Fifteen patients from group 2 showed conjunctival autograft ischemia at 24 h postoperative (30%), which disappeared by the first postoperative month. At 12 months postoperatively, the recurrence rate was 16% (n=8) in Group A, and 6% (n=3) in Group B. No statistically significant difference between groups was found (Fisher test p=0.7122).


Conjunctival autograft with Subconjunctival bevacizumab injection may decrease the recurrence rate of primary pterygium surgery . Although it would also be necessary to consider in following studies the influence of several factors like: work activity, factor of the surgeon’s errors, others.

Financial Disclosure:


Back to Poster listing